Analysis of the Characteristics of the Oral Virome in Metabolic Dysfunction-Associated Fatty Liver Disease
Abstract
Objective
To investigate the characteristics of salivary and supragingival plaque viromes in patients with metabolic dysfunction-associated fatty liver disease (MAFLD), and provide new insights for noninvasive oral screening and ecological intervention for MAFLD.
Methods
This study included 21 MAFLD patients and 20 healthy controls. Saliva and supragingival plaque samples were collected, and metagenomic sequencing was used to analyze the characteristics of the oral virome.
Results
The α-diversity and β-diversity of the salivary virome did not differ significantly between MAFLD patients and healthy individuals (P > 0.05). However, compared with healthy individuals, the α-diversity (Shannon index) and β-diversity (Bray–Curtis distance) of the supragingival plaque virome showed significant differences (P = 0.0303, P = 0.001). For species with a relative abundance greater than 0.1%, 14 viral species in saliva and 5 in supragingival plaque differed significantly in relative abundance between the two groups (P < 0.05), with multiple Streptococcus phages enriched in the saliva of MAFLD patients. LEfSe and random forest analyses identified potential biomarkers in saliva and supragingival plaque. Receiver operating characteristic (ROC) curve analysis showed strong diagnostic performance for these biomarkers in both saliva (area under the curve [AUC] = 0.9548, 95% CI: 0.8898-1.0000) and supragingival plaque (AUC = 0.8952, 95% CI: 0.7774-1.0000). Spearman correlation analysis revealed associations between viral species in saliva or supragingival plaque and various disease indicators (P < 0.05). Compared with healthy individuals, MAFLD patients showed higher node counts, significant relationship numbers, and average node degrees in the co-occurrence networks of salivary and supragingival plaque viromes.
Conclusion
Differences in the species composition and structure of the oral virome between MAFLD patients and healthy individuals suggest that oral viral species could serve as potential biomarkers for diagnosing MAFLD.
Keywords: Fatty liver/metabolism, Virome, Oral microbiota, Metagenome
Full Text:
PDFReferences
ESLAM M, El-SERAG H B, FRANCQUE S, et al. Metabolic (dysfunction)-associated fatty liver disease in individuals of normal weight. Nat Rev Gastroenterol Hepatol, 2022, 19(10): 638-651. doi: 10. 1038/s41575-022-00635-5.
HAGSTRÖM H, SHANG Y, HEGMAR H, et al. Natural history and progression of metabolic dysfunction-associated steatotic liver disease. Lancet Gastroenterol Hepatol, 2024, 9(10): 944-956. doi: 10.1016/s2468-1253(24)00193-6.
PORTINCASA P, KHALIL M, MAHDI L, et al. Metabolic Dysfunction-Associated Steatotic Liver Disease: From Pathogenesis to Current Therapeutic Options. Int J Mol Sci, 2024, 25(11): 5640. doi: 10.3390/ijms25115640.
FILIPOVIC B, MARJANOVIC-HALJILJI M, MIJAC D, et al. Molecular Aspects of MAFLD-New Insights on Pathogenesis and Treatment. Curr Issues Mol Biol, 2023, 45(11): 9132-9148. doi: 10.3390/cimb45110573.
CLARE K, DILLON J F, BRENNAN P N. Reactive Oxygen Species and Oxidative Stress in the Pathogenesis of MAFLD. J Clin Transl Hepatol, 2022, 10(5): 939-946. doi: 10.14218/jcth.2022.00067.
KURAJI R, SEKINO S, KAPILA Y, et al. Periodontal disease-related nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: An emerging concept of oral-liver axis. Periodontol 2000, 2021, 87(1): 204-240. doi: 10.1111/prd.12387.
KUROE K, FURUTA M, TAKEUCHI K, et al. Association between periodontitis and fibrotic progression of non-alcoholic fatty liver among Japanese adults. J Clin Periodontol, 2021, 48(3): 368-377. doi: 10.1111/jcpe.13415.
ZEYBEL M, ARIF M, LI X, et al. Multiomics Analysis Reveals the Impact of Microbiota on Host Metabolism in Hepatic Steatosis. Adv Sci (Weinh), 2022, 9(11): e2104373. doi: 10.1002/advs.202104373.
WANG M, LI L, QIAN J, et al. Periodontitis salivary microbiota exacerbates nonalcoholic fatty liver disease in high-fat diet-induced obese mice. iScience, 2023, 26(4): 106346. doi: 10.1016/j.isci.2023.106346.
ZHOU L J, CHEN B Y, LI Y L, et al. Oral Microbiome and Systemic Diseases. J Sichuan Univ (Med Sci), 2023, 54(1): 1-6. doi: 10.12182/ 20230160504.
ZHANG K K, SUN Y, PAN Y H. Developments in Research on the Relationship Between Porphyromonas gingivalis and Non-Oral Diseases. J Sichuan Univ (Med Sci), 2023, 54(1): 20-26. doi: 10.12182/20230160509.
LIANG G, BUSHMAN F D. The human virome: assembly, composition and host interactions. Nat Rev Microbiol, 2021, 19(8): 514-527. doi: 10. 1038/s41579-021-00536-5.
MARTÍNEZ A, KURAJI R, KAPILA Y L. The human oral virome: Shedding light on the dark matter. Periodontol 2000, 2021, 87(1): 282-298. doi: 10.1111/prd.12396.
YANG F, XIONG L, LI M, et al. A signature-protein-based approach for accurate and efficient profiling of the human gut virome. Cell Rep Methods, 2025: 101250. doi: 10.1016/j.crmeth.2025.101250.
ZHAO G, VATANEN T, DROIT L, et al. Intestinal virome changes precede autoimmunity in type Ⅰ diabetes-susceptible children. Proc Natl Acad Sci U S A, 2017, 114(30): E6166-e6175. doi: 10.1073/pnas. 1706359114.
MA Y, YOU X, MAI G, et al. A human gut phage catalog correlates the gut phageome with type 2 diabetes. Microbiome, 2018, 6(1): 24. doi: 10. 1186/s40168-018-0410-y.
YANG K, NIU J, ZUO T, et al. Alterations in the Gut Virome in Obesity and Type 2 Diabetes Mellitus. Gastroenterology, 2021, 161(4): 1257-1269. e13. doi: 10.1053/j.gastro.2021.06.056.
YE H L, ZHI M F, CHEN B Y, et al. Alterations of oral and gut viromes in hypertension and/or periodontitis. mSystems, 2024, 9(1): e0116923. doi: 10.1128/msystems.01169-23.
CHEN B Y, LIN W Z, LI Y L, et al. Characteristics and Correlations of the Oral and Gut Fungal Microbiome with Hypertension. Microbiol Spectr, 2023, 11(1): e0195622. doi: 10.1128/spectrum.01956-22.
NIU C, TU Y, JIN Q, et al. Mapping the human oral and gut fungal microbiota in patients with metabolic dysfunction-associated fatty liver disease. Front Cell Infect Microbiol, 2023, 13: 1157368. doi: 10.3389/fcimb.2023.1157368.
VALENZUELA R, FARÍAS C, MUÑOZ Y, et al. Interrelationship between alcohol consumption, overnutrition, and pharmacotherapy for liver steatosis: Considerations and proposals. Mol Cell Endocrinol, 2026, 611: 112676. doi: 10.1016/j.mce.2025.112676.
HABIBULLAH M, JEMMIEH K, OUDA A, et al. Metabolic-associated fatty liver disease: a selective review of pathogenesis, diagnostic approaches, and therapeutic strategies. Front Med (Lausanne), 2024, 11: 1291501. doi: 10.3389/fmed.2024.1291501.
IMAI J, KITAMOTO S, KAMADA N. The pathogenic oral-gut-liver axis: new understandings and clinical implications. Expert Rev Clin Immunol, 2021, 17(7): 727-736. doi: 10.1080/1744666x.2021.1935877.
XU T, JIAO X, LIU G, et al. Oral virome metagenomic catalog links Porphyromonas gingivalis phages to obesity and type 2 diabetes. Cell Rep Med, 2025, 6(9): 102325. doi: 10.1016/j.xcrm.2025.102325.
WANG M, YAN L Y, QIAO C Y, et al. Ecological shifts of salivary microbiota associated with metabolic-associated fatty liver disease. Front Cell Infect Microbiol, 2023, 13: 1131255. doi: 10.3389/fcimb.2023. 1131255.
HUANG J, ZHAO R, MA Q, et al. Correlation between saliva and subgingival plaque microbial community structure and its influencing factors in patients with implant restoration. Chinese Journal of Practical Stomatology, 2023, 16(1): 54-61. doi: 10.19538/j.kq.2023.01.010.
GEM H, EBADI M, SEBASTIAN G, et al. A sex-dependent salivary bacterium influences oral mucositis severity after allogeneic hematopoietic cell transplantation. NPJ Biofilms Microbiomes, 2024, 10(1): 140. doi: 10.1038/s41522-024-00611-8.
MARK WELCH J L, RAMÍREZ-PUEBLA S T, BORISY G G. Oral Microbiome Geography: Micron-Scale Habitat and Niche. Cell Host Microbe, 2020, 28(2): 160-168. doi: 10.1016/j.chom.2020.07.009.
SAKANAKA A, FURUNO M, ISHIKAWA A, et al. Diabetes alters the supragingival microbiome through plasma-to-saliva migration of glucose and fructose. Microbiome, 2025. doi: 10.1186/s40168-025-02256-x.
LANG S, DEMIR M, MARTIN A, et al. Intestinal Virome Signature Associated With Severity of Nonalcoholic Fatty Liver Disease. Gastroenterology, 2020, 159(5): 1839-1852. doi: 10.1053/j.gastro.2020.07.005.
KONG C, LIU G, KALADY M F, et al. Dysbiosis of the stool DNA and RNA virome in Crohn's disease. J Med Virol, 2023, 95(2): e28573. doi: 10. 1002/jmv.28573.
Refbacks
- There are currently no refbacks.
